Browsing by Author "Bertoglia, María Paz"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Effectiveness and duration of a second COVID-19 vaccine booster
    (2022) Jara, Alejandro; Cuadrado, Cristobal; Undurraga Fourcade, Eduardo Andrés; García, Christian; Najera, Manuel; Bertoglia, María Paz; Vergara, Verónica; Fernández, Jorge; García, Heriberto; Araos, Rafael
    Using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluated the effectiveness against COVID-19 related ICU admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series plus a homologous booster, and CoronaVac primary series plus an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimated the vaccine effectiveness weekly from February 14 to August 15, 2022, by estimating hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot was 88.2% (95%CI, 86.2-89.9) and 90.5% (95%CI 89.4-91.4) against ICU admissions and death, respectively. Vaccine effectiveness showed a mild decrease for all regimens and outcomes, probably associated with the introduction of BA.4 and BA.5 Omicron sub-lineages and immunity waning. The duration of effectiveness suggests that no additional boosters are needed six months following a second booster shot.
  • Thumbnail Image
    Item
    Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile
    (2023) Jara Vallejos, Alejandro Antonio; Cuadrado, Cristóbal; Undurraga Fourcade, Eduardo Andrés; García, Christian; Nájera, Manuel; Bertoglia, María Paz; Vergara, Verónica; Fernández, Jorge; García-Escorza, Heriberto; Araos, Rafael
    In light of the ongoing COVID-19 pandemic and the emergence of new SARSCoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19- related intensive care unit (ICU) admissions and death of mRNA based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over nonvaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes,probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning ofimmunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting.
  • Thumbnail Image
    Item
    SARS-CoV-2 Antibody Prevalence among 85,529 Healthcare Workers following the First Wave of COVID-19 in Chile
    (2021) Zuñiga, Marcela; O'Ryan, Miguel; Bertoglia, María Paz; Bravo Valenzuela, Paulina Fabiola; Lagomarcino, Anne J.; Muñoz, Sergio; Peña Alonso, Alfredo; Rodriguez, María Andrea; Vial, Pablo A.
    Background: Healthcare workers (HCWs) are at increased risk for SARS-CoV-2 infection, however not all face the same risk. We aimed to determine antibody prevalence and risk factors associated with seropositivity in the Chilean HCW community. Methods: This was a nationwide, cross-sectional study consisting of a questionnaire and COVID-19 antibody testing. All HCWs in the Chilean public health care system were invited to participate three to four months following the peak of the country's first wave. Findings: Overall SARS-Cov-2 blood antibody positivity by fingerstick or venipuncture in 85 529 HCWs was 7 · 2%, ranging from 1 · 6% to 12 · 4% between regions. SARS-Cov-2 positive PCR results were self-reported in 8 330 individuals (9 · 7%) of which 47% were seropositive. Overall 10 863 (12 · 7%) either reported prior PCR positive results and/or were seropositive. Several factors were independently associated with higher IRR for seropositivity, including working in hospital (IRR 1·484), medicine/surgery w ards (IRR 1·383), emergency room (IRR 1·266), and night shifts (IRR 1·616), as were history of contact with a confirmed case (IRR 1·462), and use of public transport (IRR 1·367). These variables remained significant when including self-reported PCR positive cases in the model. Interpretation: HCWs in the hospital were at highest risk for COVID-19, especially if working in medicine/surgery wards or emergency rooms, in night shifts, older age, exposed to confirmed cases and/or using public transport. Antibody results using lateral flow likely underestimated true infection rates by nearly 40-50%. Nevertheless, risk factors were sustained when adjusting for self-reported PCR positive cases.